Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Tandem Diabetes Care (TNDM) and Hims & Hers Health (HIMS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vir Biotechnology (VIR – Research Report), Tandem Diabetes Care (TNDM – Research Report) and Hims & Hers Health (HIMS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vir Biotechnology (VIR)
In a report released today, Michael Ulz from Morgan Stanley reiterated a Buy rating on Vir Biotechnology, with a price target of $24.00. The company’s shares closed last Monday at $7.43, close to its 52-week low of $6.40.
According to TipRanks.com, Ulz is a 2-star analyst with an average return of
Vir Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $18.00, representing a 138.7% upside. In a report issued on February 9, Needham also maintained a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Tandem Diabetes Care (TNDM)
In a report released today, Travis Steed from Bank of America Securities reiterated a Hold rating on Tandem Diabetes Care, with a price target of $35.00. The company’s shares closed last Monday at $28.26.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Tandem Diabetes Care has an analyst consensus of Moderate Buy, with a price target consensus of $29.31, representing a 14.5% upside. In a report issued on February 20, Morgan Stanley also maintained a Hold rating on the stock with a $23.00 price target.
Hims & Hers Health (HIMS)
Bank of America Securities analyst Allen Lutz maintained a Sell rating on Hims & Hers Health yesterday and set a price target of $13.00. The company’s shares closed last Monday at $15.51, close to its 52-week low of $11.20.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Currently, the analyst consensus on Hims & Hers Health is a Hold with an average price target of $30.58, implying a 93.6% upside from current levels. In a report issued on February 9, Citi also maintained a Sell rating on the stock with a $16.50 price target.
